Dr. Heidi Zhang is the Executive Vice President and Head of Technical Operations at Tune Therapeutics where the focus is epigenetic therapy. Heidi is a seasoned scientific executive who has led CMC organizations and product development teams across biotech and pharma companies, including Juno, Genentech, Novartis, and Amgen. Prior to Tune, Heidi was the Vice President of Cell Therapy Product & Analytical Development at Bristol Myers-Squibb. Her many accomplishments in science and leadership include the commercial launch of numerous life-saving medicines – including recent cell therapies Abecma and Breyanzi.
Heidi Zhang, PhD